{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:50:35Z","timestamp":1769075435653,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006020","name":"Center for Translational Molecular Medicine","doi-asserted-by":"publisher","award":["03O-104"],"award-info":[{"award-number":["03O-104"]}],"id":[{"id":"10.13039\/501100006020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13058-016-0742-0","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T08:00:33Z","timestamp":1470384033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Claudette E.","family":"Loo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisanne S.","family":"Rigter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Pengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jeanne T. F. D. Vrancken","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G. A.","family":"Gilhuijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"30","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96\u2013102.","journal-title":"J Natl Cancer Inst Monogr."},{"issue":"5","key":"742_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778\u201385.","journal-title":"J Clin Oncol"},{"issue":"7","key":"742_CR3","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483\u201393.","journal-title":"J Clin Oncol"},{"issue":"4","key":"742_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/cncr.10741","volume":"95","author":"ER Fisher","year":"2002","unstructured":"Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95(4):681\u201395.","journal-title":"Cancer"},{"issue":"1","key":"742_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/jcp.54.1.20","volume":"54","author":"H Denley","year":"2001","unstructured":"Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol. 2001;54(1):20\u20134.","journal-title":"J Clin Pathol"},{"issue":"30","key":"742_CR6","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1200\/JCO.2007.12.2747","volume":"25","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25(30):4772\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"742_CR7","first-page":"699","volume":"20","author":"S Chuthapisith","year":"2008","unstructured":"Chuthapisith S, Eremin JM, Eremin O. Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (Review). Oncol Rep. 2008;20(4):699\u2013703.","journal-title":"Oncol Rep"},{"issue":"16","key":"742_CR8","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-07-4756","volume":"14","author":"C Desmedt","year":"2008","unstructured":"Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158\u201365.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"742_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s12094-008-0265-y","volume":"10","author":"A Sanchez-Munoz","year":"2008","unstructured":"Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Duenas-Garcia R, Jaen-Morago A, Ortega-Granados AL, Fernandez-Navarro M, Torre-Cabrera C, Duenas B, Rueda AI, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol. 2008;10(10):646\u201353.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"742_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-009-0499-6","volume":"119","author":"JJ Ronde de","year":"2010","unstructured":"de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119(1):119\u201326.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"742_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10549-005-9036-4","volume":"93","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Johnston SR. Endocrine therapy\u2013current benefits and limitations. Breast Cancer Res Treat. 2005;93 Suppl 1:S3\u2013S10.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"742_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10147-006-0575-4","volume":"11","author":"E Tokunaga","year":"2006","unstructured":"Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006;11(3):199\u2013208.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"742_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/sj.bjc.6600210","volume":"86","author":"P Chollet","year":"2002","unstructured":"Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86(7):1041\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"742_CR14","first-page":"297","volume":"180","author":"DM Sataloff","year":"1995","unstructured":"Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297\u2013306.","journal-title":"J Am Coll Surg"},{"issue":"8","key":"742_CR15","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672\u201385.","journal-title":"J Clin Oncol"},{"issue":"22","key":"742_CR16","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","volume":"19","author":"JA Hage van der","year":"2001","unstructured":"van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224\u201337.","journal-title":"J Clin Oncol"},{"issue":"15","key":"742_CR17","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol"},{"issue":"1","key":"742_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO;2-2","volume":"78","author":"DC Abraham","year":"1996","unstructured":"Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;78(1):91\u2013100.","journal-title":"Cancer"},{"issue":"2","key":"742_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1023\/A:1014856713942","volume":"72","author":"C Balu-Maestro","year":"2002","unstructured":"Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002;72(2):145\u201352.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"742_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/B:BREA.0000025409.69516.23","volume":"85","author":"M Bodini","year":"2004","unstructured":"Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat. 2004;85(3):211\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"742_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2214\/ajr.184.3.01840868","volume":"184","author":"E Yeh","year":"2005","unstructured":"Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005;184(3):868\u201377.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"742_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ol.2012.1004","volume":"5","author":"Y Hayashi","year":"2013","unstructured":"Hayashi Y, Takei H, Nozu S, Tochigi Y, Ichikawa A, Kobayashi N, Kurosumi M, Inoue K, Yoshida T, Nagai SE, et al. Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett. 2013;5(1):83\u20139.","journal-title":"Oncol Lett"},{"issue":"3","key":"742_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/SLA.0b013e31819a6e01","volume":"249","author":"JH Chen","year":"2009","unstructured":"Chen JH, Feig BA, Hsiang DJ, Butler JA, Mehta RS, Bahri S, Nalcioglu O, Su MY. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009;249(3):448\u201354.","journal-title":"Ann Surg"},{"issue":"11","key":"742_CR24","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1245\/s10434-011-1912-z","volume":"18","author":"KP McGuire","year":"2011","unstructured":"McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18(11):3149\u201354.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"742_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2015150013","volume":"279","author":"NM Hylton","year":"2015","unstructured":"Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657\/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2015;279(1):44\u201355.","journal-title":"Radiology"},{"key":"742_CR26","doi-asserted-by":"crossref","unstructured":"Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010:Apr 6. [Epub ahead of print].","DOI":"10.1245\/s10434-010-1008-1"},{"issue":"15","key":"742_CR27","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1200\/JCO.2005.09.077","volume":"23","author":"J Hannemann","year":"2005","unstructured":"Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005;23(15):3331\u201342.","journal-title":"J Clin Oncol"},{"issue":"5","key":"742_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2214\/AJR.07.3567","volume":"191","author":"CE Loo","year":"2008","unstructured":"Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJ, Gilhuijs KG. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol. 2008;191(5):1331\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"742_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1148\/radiol.2253011582","volume":"225","author":"KG Gilhuijs","year":"2002","unstructured":"Gilhuijs KG, Deurloo EE, Muller SH, Peterse JL, Schultze Kool LJ. Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions initial results. Radiology. 2002;225(3):907\u201316.","journal-title":"Radiology"},{"issue":"1","key":"742_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1148\/radiology.211.1.r99ap38101","volume":"211","author":"CK Kuhl","year":"1999","unstructured":"Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology. 1999;211(1):101\u201310.","journal-title":"Radiology"},{"key":"742_CR31","volume-title":"Breast Imaging and Reporting Data System (BI-RADS)","author":"American College of Radiology","year":"2003","unstructured":"American College of Radiology. Breast Imaging and Reporting Data System (BI-RADS). Reston: American College of Radiology; 2003."},{"issue":"22","key":"742_CR32","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","volume":"21","author":"HD Bear","year":"2003","unstructured":"Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165\u201374.","journal-title":"J Clin Oncol"},{"issue":"25","key":"742_CR33","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","volume":"23","author":"MC Green","year":"2005","unstructured":"Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23(25):5983\u201392.","journal-title":"J Clin Oncol"},{"issue":"15","key":"742_CR34","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"742_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","volume":"140","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63\u201371.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"742_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10549-011-1488-0","volume":"131","author":"EH Lips","year":"2012","unstructured":"Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 2012;131(3):827\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"742_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2214\/ajr.181.5.1811275","volume":"181","author":"EL Rosen","year":"2003","unstructured":"Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV, Dewhirst MW. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2003;181(5):1275\u201382.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"742_CR38","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/sj.bjc.6601710","volume":"90","author":"RM Warren","year":"2004","unstructured":"Warren RM, Bobrow LG, Earl HM, Britton PD, Gopalan D, Purushotham AD, Wishart GC, Benson JR, Hollingworth W. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90(7):1349\u201360.","journal-title":"Br J Cancer"},{"issue":"10","key":"742_CR39","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cncr.27995","volume":"119","author":"JF Los Santos De","year":"2013","unstructured":"De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119(10):1776\u201383.","journal-title":"Cancer"},{"issue":"3","key":"742_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00130404-200605000-00010","volume":"12","author":"MS Kwong","year":"2006","unstructured":"Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006;12(3):212\u201321.","journal-title":"Cancer J"},{"issue":"833","key":"742_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1259\/bjr.70.833.9227225","volume":"70","author":"A Rieber","year":"1997","unstructured":"Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, Tomczak R. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997;70(833):452\u20138.","journal-title":"Br J Radiol"},{"issue":"1","key":"742_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cncr.23130","volume":"112","author":"JH Chen","year":"2008","unstructured":"Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112(1):17\u201326.","journal-title":"Cancer"},{"issue":"4","key":"742_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/SLA.0b013e3181c5dda3","volume":"251","author":"ME Straver","year":"2010","unstructured":"Straver ME, Loo CE, Rutgers EJ, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251(4):701\u20137.","journal-title":"Ann Surg"},{"issue":"6","key":"742_CR44","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2214\/ajr.184.6.01841774","volume":"184","author":"SC Partridge","year":"2005","unstructured":"Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005;184(6):1774\u201381.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"742_CR45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1148\/radiol.13121801","volume":"268","author":"A Yi","year":"2013","unstructured":"Yi A, Cho N, Im SA, Chang JM, Kim SJ, Moon HG, Han W, Park IA, Noh DY, Moon WK. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology. 2013;268(3):662\u201372.","journal-title":"Radiology"},{"issue":"2","key":"742_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jmri.24351","volume":"40","author":"NF Jafri","year":"2014","unstructured":"Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014;40(2):476\u201382.","journal-title":"J Magn Reson Imaging"},{"key":"742_CR47","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u20131717.","DOI":"10.1016\/S0140-6736(05)66544-0"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-016-0742-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0742-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T02:56:48Z","timestamp":1568257008000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-016-0742-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1186\/s13058-016-0742-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"article-number":"82"}}